P-004

P-004 is a clinical-stage pipeline candidate being developed by Pangea Pharmaceuticals for the treatment of pain and inflammation. Pangea Pharmaceuticals is a specialty pharmaceutical company that focuses on the development of reformulated or generic products, typically utilizing the 505(b)(2) regulatory pathway to improve upon existing therapies. As such, P-004 is likely a new formulation, dosage form, or delivery method of an established analgesic or anti-inflammatory agent. Detailed technical information regarding its molecular target, specific modality, and clinical development phase is currently proprietary and has not been released by the company.